The Pharmacy Times® Diabetes Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of chronic diseases that result in high blood glucose.
September 15th 2025
GLP-1 receptor agonists enhance glycemic control and weight management in youth with type 2 diabetes (T2D) and obesity, while safety concerns persist.
FDA Delays Approval Decision for Sanofi's Insulin Glargine, Lixisenatide Pen for Diabetes
September 1st 2016Sanofi has submitted updated information to the FDA as part of a previously submitted New Drug Application (NDA) for its investigational once-daily, fixed-ratio combination of basal insulin glargine 100 units/mL (Lantus) and lixisenatide (Adlyxin) to treat type 2 diabetes in adults.
Read More